Use of dexrazoxane as a cardioprotectant in patients receiving doxorubicin or epirubicin chemotherapy for the treatment of cancer. The Provincial Systemic Treatment Disease Site Group.

Cancer prevention & control : CPC = Prévention & contrôle en cancérologie : PCC

Volumn 3, Issue 2, 1999, Pages 145-159

  Seymour, L ^a   Bramwell, V ^a   Moran, L A ^a  

^a Institut national du cancer du Canada   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; ANTINEOPLASTIC ANTIBIOTIC; CARDIOVASCULAR AGENT; DOXORUBICIN; EPIRUBICIN; RAZOXANE;

AGED; ARTICLE; BREAST TUMOR; CHEMICALLY INDUCED DISORDER; CLINICAL TRIAL; COMPARATIVE STUDY; CONGESTIVE HEART FAILURE; CONTROLLED CLINICAL TRIAL; DRUG ADMINISTRATION; DRUG EFFECT; EVIDENCE BASED MEDICINE; FEMALE; HEART; HUMAN; NEOPLASM; PRACTICE GUIDELINE; RANDOMIZED CONTROLLED TRIAL; RISK; TIME; TREATMENT OUTCOME;

AGED; ANTIBIOTICS, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CARDIOVASCULAR AGENTS; CLINICAL TRIALS; DOXORUBICIN; DRUG ADMINISTRATION SCHEDULE; EPIRUBICIN; EVIDENCE-BASED MEDICINE; FEMALE; HEART; HEART FAILURE, CONGESTIVE; HUMANS; NEOPLASMS; ODDS RATIO; RANDOMIZED CONTROLLED TRIALS; RAZOXANE; TIME FACTORS; TREATMENT OUTCOME;

EID: 0033113566     PISSN: 1206548X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (0)